Trials / Completed
CompletedNCT03232177
Anagre Cap. in Patients With High-Risk Essential Thrombocythemia
A Multicenter, Open-label, Clinical Study for Efficacy and Safety Evaluation of Anagrelide in Patients With Treatment-naïve, High-risk Essential Thrombocythemia as a Primary Treatment
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Yuhan Corporation · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the efficacy and safety according to incremental dosing for 8 weeks and duration of administration for 1 year in patients with high-risk essential thrombocythemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anagre Cap. | from 0.5mg twice a day to maximally increase total10mg in 8 weeks and maintain maximal tolerable dose to 104 weeks |
Timeline
- Start date
- 2017-06-05
- Primary completion
- 2020-12-05
- Completion
- 2020-12-05
- First posted
- 2017-07-27
- Last updated
- 2021-07-21
Locations
21 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03232177. Inclusion in this directory is not an endorsement.